{"id":296032,"date":"2026-08-25T00:00:00","date_gmt":"2026-08-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0002-2023-biopharma-asthma-access-reimbursement-access-reimbursement-asthma-us\/"},"modified":"2026-09-20T11:14:29","modified_gmt":"2026-09-20T11:14:29","slug":"acreim0002-2026-biopharma-asthma-access-reimbursement-access-reimbursement-asthma-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0002-2026-biopharma-asthma-access-reimbursement-access-reimbursement-asthma-us\/","title":{"rendered":"Asthma &#8211; Access &#038; Reimbursement &#8211; Access &#038; Reimbursement &#8211; Asthma (US)"},"content":{"rendered":"<p>The dynamics within the <abbr title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr title=\"inhaled corticosteroid\">ICS<\/abbr> <abbr title=\"fixed-dose combination\">FDC<\/abbr>, <abbr title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>, <abbr title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>\/<abbr title=\"inhaled corticosteroid\">ICS<\/abbr> <abbr title=\"fixed-dose combination\">FDC<\/abbr>, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded <abbr title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr title=\"inhaled corticosteroid\">ICS<\/abbr> <abbr title=\"fixed-dose combination\">FDC<\/abbr>s (e.g., GSK\u2019s Advair, AstraZeneca\u2019s Symbicort) will likely decline further as uptake of generic \/ branded generic agents strengthens. Each biologic has been carving out its own niche among the subpopulations of severe, refractory asthma, with Roche\u2019s Xolair used in patients with allergic asthma, <abbr title=\"interleukin\">IL<\/abbr>-5 inhibitors and Sanofi \/ Regeneron\u2019s Dupixent in patients with eosinophilic asthma, and AstraZeneca\u2019s Tezspire in patients independent of T<sub>H<\/sub>2 status. However, the 2025 approval of the first ultra-long-acting <abbr title=\"interleukin\">IL<\/abbr>-5 inhibitor (GSK\u2019s Exdensur) may alter the competitive landscape among the <abbr title=\"interleukin\">IL<\/abbr>-5 inhibitors. Overall, marketers of current and emerging asthma agents will face increasing challenges as they strive to retain \/ gain a favorable formulary position and market uptake in this crowded market.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Which asthma therapies have favorable formulary placement, and how do payers manage the use and costs of these therapies?<\/li>\n<li>How do reimbursement restrictions affect physicians\u2019 prescribing of <abbr title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr title=\"inhaled corticosteroid\">ICS<\/abbr> <abbr title=\"fixed-dose combination\">FDC<\/abbr>s, AstraZeneca\u2019s Airsupra, Boehringer Ingelheim\u2019s Spiriva, GSK\u2019s Trelegy, and biologics to their asthma patients?<\/li>\n<li>How do payers \/ physicians expect emerging inhaled therapies, notably AstraZeneca\u2019s Breztri and Teva\u2019s albuterol \/ fluticasone propionate, to affect access to \/ prescribing of current branded therapies, and what are their perceptions of the emerging long-acting anti-<abbr title=\"thymic stromal lymphopoietin\">TSLP<\/abbr> Generate Biomedicines\u2019 GB-0895?<\/li>\n<li>How are payers covering GSK\u2019s Exdensur, and has it impacted coverage of established <abbr title=\"interleukin\">IL<\/abbr>-5 inhibitors (i.e., GSK\u2019s Nucala, AstraZeneca\u2019s Fasenra)?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Leveraging Clarivate\u2019s proprietary data sources and surveys with physicians and payers, Access &#038; Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of payer policy on physician prescribing behavior in the United States. Through detailed analyses of drug coverage, restriction policies, and contracting, as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies, this report enables you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Identify and learn how to overcome roadblocks to market access to best position your brand.<\/li>\n<li>Identify key stakeholders and reimbursement drivers and assess the impact that reimbursement decisions have on treatment selection.<\/li>\n<li>Evaluate competitor strategies for securing favorable market access terms.<\/li>\n<\/ul>\n<p><b>Geography: <\/b>United States<\/p>\n<p><strong>Primary research: <\/strong>Survey of 50 U.S. pulmonologists and 50 U.S. allergists, 30 U.S. <abbr title=\"managed care organization\">MCO<\/abbr> <abbr title=\"pharmacy director\">PD<\/abbr>s\/<abbr title=\"medical director\">MD<\/abbr>s, and interviews with 2 U.S. <abbr title=\"managed care organization\">MCO<\/abbr> <abbr title=\"pharmacy director\">PD<\/abbr>s\/<abbr title=\"medical director\">MD<\/abbr>s<\/p>\n<p><strong>Fingertip Formulary: <\/strong>Formulary coverage by commercial plans covering more than 187 million lives nationally.<\/p>\n<p><strong>Real-world data:<\/strong> U.S. pharmacy and medical claims data<\/p>\n<p><strong>Key<\/strong><strong> drugs<\/strong>: Advair, Symbicort, Spiriva, Trelegy, Xolair, Nucala, Cinqair, Fasenra, Dupixent, Tezspire, Exdensur<\/p>\n","protected":false},"template":"","class_list":["post-296032","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-asthma","biopharma-therapy-areas-respiratory","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}